The disclosure relates to methods to prevent, treat, or slow the progression viral-associated lymphoproliferative disorders, EBV-associated lymphoproliferative disorders, and post-transplant lymphoproliferative disorders. In the methods, a TGF-beta antagonist, e.g., an anti-TGF-beta antibody is administered to a subject. Methods for treating viral-associated lymphoproliferative disorders and for enhancing T-cell responsiveness to a viral-associated lymphoproliferative disorder by administering a TGF-beta antagonist are also described.
